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Previous studies showed the presence of Campylobacter ureolyticus in a large proportion of diarrhoeal samples from
patients in Ireland. This emerging gastrointestinal pathogen was the second most common Campylobacter species
detected in patients presenting with gastroenteritis, surpassed only by C. jejuni. However, the source of C. ureolyticus
infections in humans remains unknown. The aim of this study was to investigate the presence of C. ureolyticus in a
range of domestic animals. Over a period of 6 months, 164 samples collected from various domestic animals were
tested using molecular method based on detection of the C. ureolyticus specific hsp60 gene. These included canine
faeces (n = 44), feline faeces (n = 31) and porcine faeces (n = 89). C. ureolyticus was detected in 32% (10/31) of feline
faeces, 9% (4/44) of canine faeces and 18% (16/89) of porcine faeces. Random Amplified Polymorphic DNA (RAPD)
analysis of C. ureolyticus isolates showed that an isolate from a cat is genetically similar to a strain isolated from a
patient presenting with gastroenteritis.
This study reports the first detection and isolation of this organism in domestic animals in Ireland, with a potential
source for human infection. Together with the previously reported detection of C. ureolyticus in bovine samples, it is
likely that this emerging pathogen has a zoonotic potential.
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Infections with Campylobacter spp. account for a signifi-
cant proportion of the reported cases of bacterial gastro-
enteritis worldwide [1].
Understanding the spread of campylobacter and its trans-
mission from environmental sources to humans is essential
for disease control and prevention. Campylobacter spp.
have been detected in a variety of sources, such as wild
birds and rivers [2,3]. However, campylobacteriosis is
mostly a disease of zoonotic origin - inappropriate hand-
ling and consumption of undercooked, contaminated meat
and other food products of animal origin, such as unpas-
teurised milk, are the most important risk factors for
Campylobacter spp. infection [4]. While chickens and cat-
tle are the most common animal reservoirs of Campylo-
bacter spp, particularly C. jejuni and C. coli, other animals,
such as pigs, sheep and dogs have also been linked to
human infections [5-7].* Correspondence: roy.sleator@cit.ie
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unless otherwise stated.Recently, molecular-based studies of the prevalence
of various Campylobacter spp. in patients presenting
with gastroenteritis in Southern Ireland, have identified
Campylobacter ureolyticus as the second most common
Campylobacter species, after C. jejuni [8]. Other studies
have detected C. ureolyticus in patients suffering from
diarrhoea [9,10], Crohn’s disease [11,12] and ulcerative
colitis [13].
However, despite being detected in a large proportion
of patients, the possible sources of human infections still
remain unclear.
In this study we investigate the presence of C. ureolyticus
in samples obtained from animals which were previously
shown to be positive for Campylobacter species such as
C. jejuni and C. coli, in order to elucidate possible routes
of transmission of this emerging pathogen to humans.Results
From November 2012 to March 2013, 164 faecal samples
were collected from domestic animals (dogs, cats and
pigs). These were tested for C. ureolyticus with species-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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results were cultured. The results are presented in Table 1.
Of 89 porcine samples tested, 16 (18%) tested positive
for the presence of Campylobacter ureolyticus (Table 1).
In Farm 1, the majority of the C. ureolyticus-positive pig-
lets were aged ≥2 months and a large proportion of piglets
6–9 days old was also positive for this organism. None of
the 16 piglets aged 4–6 weeks tested positive for C. ureoly-
ticus. Since no piglets younger than 2 months old were
available in Farm 2 at the time of testing, no comparable
data are available from this farm.
C. ureolyticus was also detected in pets in this study. A
total of 32% of cat faecal samples and 9% of dog faecal
samples were positive for this organism. These samples
were collected from both local animals and animals in
the care of two Cork veterinary hospitals.
All PCR-positive samples were inoculated on NAV
medium. Among all 30 animal samples cultured, one
strain of C. ureolyticus was isolated from cat faeces. To
investigate the genetic similarity of this strain (CIT 012)
to isolates obtained from patients’ faecal samples and
culture collection strains, RAPD analysis with (GTG)5
primer was performed (Figure 1).
Gel profiles were compared and clustered on the basis
of pattern similarity, using Phoretix 1D Pro software,
and the obtained dendrogram is presented in Figure 2.
Feline isolate CIT 012 clustered closely with the CIT
009 isolate obtained from an elderly female suffering
from gastroenteritis.
Antibiotic susceptibility testing (AST) with disc diffusion
method showed that strain CIT 009 and CIT 012 are re-
sistant to ciprofloxacin, nalidixic acid and trimethoprim.
Discussion
The emerging role of Campylobacter ureolyticus as a po-
tential cause of human gastrointestinal illness has been of
interest to various research groups worldwide. However,
reported isolations of C. ureolyticus from animals are very
limited and mostly associated with endometrial infections
in mares [14,15], potentially linked to infertility in these
animals.
A previous study, performed by our research group,
reported the presence of C. ureolyticus in a total of 13%
of unpasteurised milk samples, collected across two dif-
ferent farms in Co. Cork, Ireland [16]. However, anTable 1 Summary of PCR-positive results obtained
throughout the study




Porcine 16 (18%) 0/16 (0.0)
Canine 4 (9%) 0/44 (0.0)
Feline 10 (32%) 1/31 (3.2)investigation into a zoonotic potential of this emerging
pathogen and its association with domestic animals,
which are common transmission vectors for other Cam-
pylobacter species such as C. jejuni, has not yet been in-
vestigated. This study was undertaken to investigate the
presence of C. ureolyticus in domestic and companion
animals using molecular and traditional approaches.
Among 89 porcine faecal swabs collected, 18% (n = 16)
tested positive for C. ureolyticus (Table 1). A similar pro-
portion of C.ureolyticus-positive animals was observed
across the two farm sites tested with 19% of pigs in Farm
1 and 17% of pigs in Farm 2 positive for this organism
(Table 2).
The overall positive sample rate was similar for the
two farms tested, despite the fact they were separated
geographically. Interestingly, a similar study by Soultos
et al. [17] investigating the prevalence of Campylobacter
coli in piglets aged 3–66 days and their sows reported
that a majority of piglets in their first days of life were
colonised with Campylobacter coli genotypes resembling
those isolated from the sow. These were often displaced
by other genotypes in 3 month old piglets. Many of the
piglets and sows carried multiple genotypes of C. coli [17].
Since no isolates were recovered from piglets in this study,
no investigation into the genetic diversity of C. ureolyticus
strains in piglets at different age was possible.
As no other study has investigated the prevalence of
C. ureolyticus in porcine samples, no direct comparison
of the levels found with these reported in this study is
possible. However, other studies report significant rates
of fastidious Campylobacter species, such as C. concisus
(9%) or C. helveticus (6%) in porcine caecal content tested
[18]. The rates reported in this study for C. ureolyticus
are comparable with those reported for other fastidious
species [18]. The high prevalence of C. ureolyticus in
the porcine gastrointestinal tract, highlights the poten-
tial for zoonotic transmission, especially if abattoir hy-
giene was not maintained at acceptable levels. This
could be of particular importance for retail products,
such as cured or smoked ham and bacon, which do not
undergo extensive heat treatment, which would other-
wise significantly decrease the number of viable bacteria
in foodstuffs. However further studies are needed to de-
termine whether consumption of such foods increases
the risk for C. ureolyticus infection in humans.
Campylobacter ureolyticus was also detected in faecal
samples collected from cats and dogs. These included
samples collected from companion household animals as
well as animals in veterinary care. A total of 9% of canine
and 32% of feline samples tested positive for the presence
of C. ureolyticus. Metagenomic studies carried out on cats,
report percentages of Campylobacter spp. as high as 10%
[19]. Moreover, Campylobacter spp. of potential clin-
ical relevance, other than C. jejuni and C. coli, such as
Figure 1 1.5% agarose gel of RAPD profiles of C. ureolyticus isolates generated with (GTG)5 primer. Lane 1: 100 bp molecular weight
marker; Lane 2: CIT 001; Lane 3: CIT 002; Lane 4: CIT 003; Lane 5: CIT 004; Lane 6: CIT 005; Lane 7: CIT 006; Lane 8: CIT 007; Lane 9: CIT 008; Lane
10: CIT 009; Lane 11: CIT 010; Lane 12: CIT 011; Lane 13: CIT 012; Lane 14: CIT 013; Lane 15: CIT 014; Lane 16: DSMZ 20703T; Lane 17: CCUG 9510;
Lane 18: CCUG 58468; Lane 19: CCUG 59897; Lane 20: 100 bp molecular weight marker.
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faeces [6]. PCR detection rates of Campylobacter spp.
from dog faeces are highly variable (58–97%) depending
on the study, geographical location and methodology
used [20].
Various factors appear to influence the level of Cam-
pylobacter spp. faecal shedding in cats and dogs. These in-
clude the age of the animal, with puppies < 6 months and
cats <36 months more frequently positive for Campylo-
bacter spp. [21-23]; housing conditions, with dogs housed
in kennels or shelters and outdoor cats with no access to
litter trays, more at risk of campylobacter infections
[23,24]; and dogs’ diet, with a higher risk of campylobacter
infection for animals fed a homemade food diet [25].
It has been shown that strains isolated from patients
with Campylobacter jejuni infections, particularly young
children, and their pets are genetically similar, con-
firming the possibility of zoonotic transmission of this
genus [26-28].
This finding is of potential importance for understanding
the possible sources of C. ureolyticus infections in humans.
The majority of patients suffering from gastroenteritis
in which C. ureolyticus was detected, were reported toFigure 2 Dendrogram of C. ureolyticus RAPD profiles. Unweighted Pair
distance tree was generated with Phoretix 1D Pro software. Highlighted isobe children <5 years old or adults >70 years old [29]. In
this study, we have shown that the C. ureolyticus strain
isolated from a cat’s faeces is genetically similar to the
isolate CIT 009 cultured from the diarrhoeal stool of an
elderly patient (Figure 2). RAPD profiles of these two
isolates were identical and clustered together with other
strains isolated from the faeces of patients aged 83 (CIT
001), 81 (CIT 010) and 3 years old (CIT 011) as well as
an isolate recovered from the blood of an elderly patient
(78 years).
The isolation of Campylobacter ureolyticus from animal
faeces is difficult, with an isolation rate of 3.2% from PCR-
positive cat samples and zero from pig and dog samples.
The difficulty in isolation can be partially attributed to a
lack of selective medium for C. ureolyticus. This organism
is sensitive to many antibiotics commonly used in media
supplements for C. jejuni or C. coli, such as cefoperazone
or cycloheximide. Moreover, the fastidious nature of the
species together with an optimal growth temperature of
37°C, rather than 42°C, make it more difficult to isolate
than, for example, C. jejuni, especially from samples,
such as faeces, which have a large number of competing
microorganisms.Group Method with Arithmetic Mean (UPGMA) with a dice coefficient
late (CIT 012) is the feline isolate.
Table 2 Summary of positive porcine faecal samples from
the two farms sampled
Number of positive samples (%)
Farm site Age of piglets
6–9 days 4–6 weeks ≥2 months Total
Farm 1 7/29 (24) 0/16 (0) 3/8 (38) 10/53 (19)
Farm 2 N/A N/A 6/36 (17) 6/36 (17)
Total 4/29 (14) 0/16 (0) 9/44 (20) 16/89 (18)
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for species such as C. jejuni or C. coli, for which use of
selective temperature, selective media and well estab-
lished protocols is possible. It has been previously shown
that among diarrhoeal samples from patients, as much
as 50% were not cultured, despite being determined to
be Campylobacter jejuni and C. coli [30,31]. Therefore,
the prevalence of fastidious Campylobacter species is
even more likely to be underestimated when traditional
culture methods, targeting mostly thermophilic species,
are employed.
The difficulty in culturing campylobacters in general,
may also be a attributed to the presence of organisms in
a viable but nonculturable state. It has been shown that
campylobacter cells which enter this state, cannot be
cultured on artificial media, despite remaining virulent
and capable of invading intestinal cells [32].
Molecular based detection offers an alternative, allow-
ing us to circumvent the problems facing traditional
culture based approaches. Therefore, despite a failure to
grow pathogenic Campylobacter spp., their detection
with molecular methods is still likely to be of clinical
significance.
Conclusion
The effect of C. ureolyticus infections on animal health
has, to date, not been investigated in any great detail. All
stools samples collected throughout this study, were non-
diarrhoeal, therefore no comparison of C. ureolyticus rates
in healthy and sick animals was possible.
Nevertheless, this is the first study reporting the pres-
ence of C. ureolyticus in samples collected from domestic
animals. Moreover, comparison of genetic profiles of iso-
lates from animal and human origins shows the potential
involvement of pets in C. ureolyticus infection, highlight-
ing its potential for zoonotic transmission.
Methods
Sample collection
Faecal samples from asymptomatic pigs (n = 89), dogs
(n = 44) and cats (n = 31) were collected between November
2012 and March 2013.
Porcine samples were obtained from piglets age 6–9
days old (n = 29), 4 weeks old (n = 16) and 2 months old(n = 44) from two separate pig farms in Southern Ireland,
located approximately 20 km apart. Piglets were swabbed
using sterile swabs (Deltalab) and the faecal samples were
placed in 15 ml conical tubes (Corning) filled to the top
with Bolton broth (Oxoid) with NAV supplement [33]
which consisted of (l−1): 2 g sodium formate (Fluka), 3 g
sodium fumarate (Fluka), 10 mg of amphotericin B, 10 mg
nalidixic acid and 20 mg of vancomycin (all supplied by
Sigma Aldrich).
Canine and feline samples were collected from local
domestic animals and animals cared for in two separate
veterinary hospitals in Co. Cork. Fresh faecal matter was
placed in 25 ml centrifuge tube (Sarstedt) filled with
Bolton Broth with NAV supplement.Sample preparation
All collected samples were immediately closed tightly
(to create anaerobic conditions) and transported to the
laboratory for incubation.
Samples were incubated aerobically at 37°C for a mini-
mum of 7 days. Following incubation, samples were tested
for the presence of C. ureolyticus using PCR. Remaining
enriched broths were kept at 37°C for culture of any posi-
tive results following molecular analysis.Molecular detection
Following incubation, 2 ml of enriched sample was
taken for molecular analysis. Samples were centrifuged
at 17,000 × g for 1 minute and bacterial DNA from the
pellet was extracted with QIAamp DNA Stool Mini Kit
(Qiagen). The presence of C. ureolyticus was investigated
as previously described [16]. In brief, C. ureolyticus-
specific primers targeting the hsp60 gene of this organism
[34] were used for analysis of the samples. Potential
PCR inhibition by the sample was monitored by includ-
ing an internal amplification control (IAC) in every PCR
reaction.
All PCR reactions consisted of 1U of HotStarTaq Plus
DNA Polymerase (Qiagen), 1 μM of each primer (Eurofins,
MWG Operon), 0.2 μM of each dNTPs (Sigma Aldrich)
and 100 ng of DNA template. The C. ureolyticus DSMZ
20703 type strain was used as a positive control for both
extraction and PCR amplification. PCR conditions were as
suggested by the Taq manufacturer and the annealing
temperature was set at 58°C for 1 minute. Amplicons were
visualised on 1.5% agarose gels and the results were inter-
preted on the basis of presence/absence of a band of
429 bp for C. ureolyticus positive samples and IAC amplifi-
cation (196 bp) for C. ureolyticus negative samples. Positive
amplicons were purified using QIAquick PCR Purification
Kit (Qiagen) and PCR positive products were sequenced
(GATC Biotech) using the hsp60 primers to ensure the
validity of the positive results.
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Samples were cultured immediately, once presumptive
positive results from the PCR were obtained, to attempt
recovery of C. ureolyticus. Enriched samples were inoc-
ulated onto NAV agar [33], consisting of (l−1) 46 g of
Anaerobe Basal Agar (Oxoid), 10 g Agar (Sigma Aldrich)
and NAV supplement described previously. Each sample
was inoculated in triplicate and incubated anaerobically
using AnaeroGen 2.5 L gas packs (Oxoid) at 37°C for up
to 14 days. Plates were checked during that period at regu-
lar intervals (3–4 days) for presumptive C. ureolyticus
colonies: flat, translucent, spreading colonies. Colony
PCR with C. ureolyticus - hsp60 primers was performed
on putative colonies. All PCR positive isolates were sent
for 16S rRNA sequencing using fD1 and rP1 primers
[35] to confirm their identity.
RAPD analysis and comparison with human isolates
Campylobacter ureolyticus strains isolated from animals
were compared with human isolates obtained from pa-
tients presenting with gastroenteritis, healthy controls and
strains available from culture collections. Details of the
isolates are shown in Table 3.
To obtain RAPD profiles, PCR reactions were carried
out with (GTG)5 primer [36] at a final concentration of
1 μM, 1U GoTaq DNA Polymerase (Promega), 0.2 μM
of each dNTPs and 100 ng of template DNA. Thermal
cycling conditions were as follows: 1 initial denaturationTable 3 Summary of the strains used in this study
Strain Gender (Age in years) Sample source
CIT 001 Male (83) Human faeces
CIT 002 Female (84) Human faeces
CIT 003 Male (65) Human faeces
CIT 004 Female (3) Human faeces Admitted to the
CIT 005 Female (3) Human faeces
CIT 006 Female (71) Human faeces
CIT 007 Female (84) Human faeces
CIT 008 Female (55) Human faeces
CIT 009 Female (83) Human faeces
CIT 010 Female (81) Human faeces
CIT 011 Female (3) Human faeces
CIT 012 Female (2) Cat faeces
CIT 013 Female (26) Human faeces
CIT 014 Male (33) Human faeces
DSMZ 20703T* Female Amniotic fluid
CCUG 9510* Male (22) Penis wound
CCUG 59468* Female Vagina
CCUG 59897* Unknown (78) Human blood
*Strains were obtained from Culture Collection, University of Göteborg, Sweden (CC
Cultures, Braunschweig, Germany.cycle at 94°C for 5 min, followed by 34 cycles of de-
naturation at 94°C for 2 min, annealing as described
later and extension at 72°C for 2 min followed by the
final extension step at 72°C for 5 min. To improve re-
producibility, the first 4 cycles were performed at lower
stringency, at annealing temperature of 36°C for 2 min,
followed by 30 cycles at 50°C for 1 min. PCR amplicons
were separated on 1.5% agarose electrophoresed at 70 V
for 90 min. The gels were stained with ethidium bromide
and visualised with UV transluminator (UVP, Cambridge,
UK). Gels were analysed using Phoretix 1D Pro software
(TotalLab) and similarities of RAPD fingerprints of all
isolates were illustrated as clusters based on the banding
patterns.
Antibiotic susceptibility of isolated CIT 009 and CIT
012 was determined using the disc diffusion method with
the following discs tested: ciprofloxacin (30 μg), nalidixic
acid (30 μg) and trimethoprim (5 μg). Both strains were
susceptible to tetracycline (20 μg), erythromycin (15 μg),
gentamicin (10 μg) and cefoperazone (30 μg) (all discs
were supplied by Oxoid). Bacterial suspension were ad-
justed to 0.5 McFarland in PBS and spread onto Mueller
Hinton agar (Sigma) supplemented with 5% defibrinated
horse blood (TCS Biosciences). Plates were incubated an-
aerobically for 48 hours; in case of insufficient growth,
plates were re-incubated for further 24 hours. Zone diam-
eters were interpreted accordingly to recommendations of
the European Committee on Antimicrobial SusceptibilityMedical history
Long term hospital stay
End stage chronic renal disease
Nursing home resident. Recurring diarrhoea
hospital with diarrhoea and vomiting. Cryptosporidium oocyst detected.
Positive for cryptosporidium oocysts
Long term hospital stay












UG) and Leibniz Institute DSMZ-German Collection of Microorganisms and Cell
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http://www.gutpathogens.com/content/6/1/9Testing [37], the British Society for Antimicrobial Chemo-
therapy [38] and breakpoints used for Campylobacter spp.
in other studies [39]. In the absence of such informa-
tion, breakpoints were decided by authors as suscep-
tible ≥10 mm and resistant ≤10 mm.
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